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Summary The cytotoxic activity of 6-mercaptopurine (6-MP) is affected by thiopurine methyltransferase
(TPMT), a genetically regulated and variable intracellular enzyme. 6-Thioguanine (6-TG), a closely related
thiopurine, is less affected by that enzyme and so it may be a more reliable drug - at least for patients with
constitutionally high TPMT activity. We attempted to assess its suitability as an alternative by comparing the
pharmacokinetics of both drugs in a small group of children with lymphoblastic leukaemia (ALL).
Patients were included who were in their second or subsequent remission, who would otherwise have
received 6-MP, and on whom pharmacokinetic data concerning 6-MP metabolism had been collected in a
previous remission. Plasma 6-TG concentrations were assayed following an oral dose of 40 mg m-2, and the
accumulation and fluctuation of intracellular (erythrocyte, RBC) 6-TG nucleotides (6-TGNs) were measured at
regular intervals during daily oral therapy.
Seven children were studied. Plasma 6-TG concentrations were low and cleared within 6 h of oral dosing. At
7 days, 6-TGN concentrations ranged from 959 to 2361 pmol 8 x 10-8 RBCs, in all cases significantly higher
(P = 0.002) than those produced by the same patients on 6-MP. After a total therapy time of 35 patient
months, a modest rise of alanine aminotransferase was seen on one occasion, otherwise no toxicity apart from
myelosuppression was encountered.
In the context used, 6-TG appears well tolerated and produces higher concentrations of intracellular
cytotoxic metabolites than 6-MP. For children constitutionally 'resistant' to the traditional drug, if not all, it
may be a preferable alternative.
6-mercaptopurine (6-MP) is traditionally and universally
used in the continuing chemotherapy of lymphoblastic
leukaemia (ALL), being important for long term survival, at
least in the 'standard risk' 'common' form of childhood ALL
(Pinkel, 1992). The 6-MP sister compound 6-thioguanine (6-
TG; 2-amino 6-mercaptopurine) has not been widely used in
this context primarily because in early clinical trials in the
1950's oral 6-TG appeared to offer no clinical advantage over
the already established 6-MP (Murphy et al., 1955). The
current differing uses of these two drugs have subsequently
evolved for reasons of custom and practice rather than on
the basis of sound pharmacology.
6-MP cytotoxicity is not related to drug dose but to the
intracellular concentration of derived active 6-thioguanine
nucleotide (6-TGN) metabolites (Herber et al., 1982; Lennard
et al., 1983). Individuals vary widely in the concentration of
6-TGNs formed from the same dose of 6-MP but multi-
variate analysis has shown that the measured concentration
of these nucleotides in red cells (RBCs) is an important
prognostic parameter for children with ALL (Lennard &
Lilleyman, 1989).
One major factor influencing the formation of 6-TGN
from 6-MP is the inherited activity of the 6-MP catabolic
enzyme thiopurine methyltransferase (TPMT) (Weinshilboum
& Sladek, 1980; Lennard et al., 1990). The higher the TPMT
activity the less 6-MP is available for the formation of 6-
TGN metabolites. Those children with high inherited levels
of TPMT form low concentrations of6-TGN and continually
take high doses of 6-MP without myelosuppression. They
also have a higher relapse rate (Lennard et al., 1990).
After a dose of 6-MP a number of intermediate meta-
bolites (some substrates for TPMT) are formed in a
metabolic sequence which ends in the formation of 6-TGNs.
6-TG, in contrast, forms 6-TGNs directly and these
metabolites are not substrates for the enzyme TPMT.
The aim of this study was to investigate the formation of
RBC 6-TGNs from oral 6-TG in a group of children who,
partly perhaps because of high inherited TPMT activity, had
previously produced relatively low concentrations despite
extended periods at full dose 6-MP. We wanted to see if such
children could form 6-TGNs more reliably and predictably
from 6-TG and whether the alternative thiopurine offered
any potential therapeutic advantage.
Materials and methods
Patient group
Children with ALL attending a single centre and not in first
remission, not in any other therapeutic trial, and previously
treated on the UKALL VIII or X protocols were eligible for
study. All such children had had 6-MP metabolism to 6-
TGN studied in their first remission and were taking, or due
to take, 6-MP as part of their continuing chemotherapy.
Study design
Oral 6-TG (40 mg m 2) was substituted for 6-MP and blood
samples taken initially at weekly or twice weekly intervals to
measure RBC 6-TGN and monitor the absolute neutrophil
count (ANC) and platelet count. After 2 months 6-TG the
frequency of blood sampling was reduced to 1 or 2 week
intervals. Blood samples were obtained under guidelines ap-
proved by the Sheffield Southern District Hospitals' Ethical
Committee. Informed consent was obtained from the parent
and patient when additional venepunctures were required.
The children were also asked if they would also take part
in a 6-TG pharmacokinetic study at the start of 6-TG
therapy. Those agreeing were given their first 6-TG dose after
an overnight fast and venous blood samples (5 ml) taken via
an intravenous cannula, before and at 0.25, 0.5, 0.75, 1.0,
1.5, 2.0, 2.5, 3.0, 4.0, 5.0 and 6.0 h for the measurement of
plasma 6-TG and RBC 6-TG and 6-TGN concentrations.
The whole blood was centrifuged immediately (2000g, 4°C,
S min) to prevent cellular metabolism of plasma 6-TG by the
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RBCs. The RBCs were washed twice in Hanks balanced salts
solution (HBSS), resuspended in 1 vol HBSS and counted.
The plasma and the washed RBCs were placed on cardice
within 10 and 20 min, respectively, of blood sampling. The
blood fractions were stored at - 20C. Breakfast was given
at 2 h with no further restriction of intake.
6-TG and 6-TGN assays
Plasma 6-TG and RBC 6-TG and 6-TGN concentrations
were measured as previously described (Lennard & Singleton,
1992). The lower limit of sensitivity for this assay is 30 pmol
6-TG m' plasma or 8 x 10-8 RBCs and 30 pmol 6-TGN
8 x 10-8 RBCs.
Results
Patients
Seven consecutive eligible children (two girls, five boys)
entered the study. They were aged from 6 to 13 years and
had experienced one to four disease relapses when studied.
At the first diagnosis of ALL these children had been aged
between 2 and 7 years with presenting white blood cell
counts of 11 to 96 x 1091-l. Four children had common
ALL, two pre-B cell ALL and one null-cell ALL.
Previous remission 6-MP metabolism
The accumulation of RBC 6-TGNs from 6-MP had been
studied in their previous remission(s) (Table I). TPMT
activities were measured when the children had been taking
100% 6-MP for at least 1 week (Lennard et al., 1990) and
ranged from 14.9 to 25.1 U ml-' RBCs (median 20.7). These
enzyme activities were at the upper end of the range (7.0 to
25.1 U ml-', median 16.4) recorded in children (n = 95)
undergoing 6-MP chemotherapy (Lennard et al., 1990).
The seven children had a total of 188 assays of RBC
6-TGN whilst taking 6-MP, over a period of 242 patient
months. The maximum duration of full dose (75mgm-2,
100%) 6-MP in earlier remissions had ranged from 6 to 96
weeks (median 28). Each child had had eight to 29 6-TGN
assays (median 13) at 100% 6-MP and 6-TGN values ranged
from 120 to 377 pmol 8 x 10-8 RBCs (median 257). For the
purpose of comparisons with 6-TG therapy the highest 6-
TGN produced after at least 4 weeks continuous 100% 6-MP
was selected as the maximum capacity for 6-TGN formation
from 6-MP.
6-TGpharmacokinetic study
Five children entered the pharmacokinetic study. The maxi-
mum 6-TG plasma concentrations ranged from 45 to
317 pmol ml-' (median 101) and the time to maximum 0.75
to 2.5 h (median 1.5). The area under the plasma concentra-
tion time curve for 0 to 6 h ranged from 149 to 488 pmol
ml1' h (median 160) and the half-life of plasma 6-TG ranged
from 0.8 to 6.2 h (median 2).
Plasma 6-TG concentrations were at or below the lower
limit of detection of the assay by 6 h post-dose (Figure 1).
The RBCs did not contain any free 6-TG but, 6-TGNs
continued to accumulate in the RBC when plasma 6-TG
concentrations had fallen to zero (Figure 2). 6-TGN concen-
trations at 6 h post-dose ranged from 144 to 574 pmol
8 x 10-8 RBCs (median 353).
RBC 6-TGN concentrations
Six children had 6-TGN concentrations measured at least
weekly over the study period. The 7th child had 6-TGN
measurements at 1 or 2 weekly intervals. At 7 days post
6-TG RBC 6-TGN concentrations ranged from 959 to
2361 pmol 8 x l0-8 RBCs in the seven children studied, this
was significantly higher than that produced by 100% 6-MP
(median difference 892 pmol, 95% C.I. 743 to 1521,
P = 0.002), (Table I). The accumulation of RBC 6-TGNs
from the start of 6-TG to the first dose adjustment are
illustrated in Figure 3. A RBC 6-TGN half-life was cal-
culated for three children after 6-TG withdrawal (two with
disease relapse and one prior to bone marrow transplanta-
tion). The loss of 6-TGN from the RBC was biphasic with an
initial ti of 4.4, 5.2 and 9 d and a tiz of 11, 9.2 and 19.2 d
respectively (Figure 4).
Myelosuppression
Of the seven children who entered the study one child did so
for 1 week only, immediately prior to entering a bone marow
transplantation programme. Six children were available for
long term study and the 6-TG based continuing chemo-
therapy was taken for 3 to 10 months (median 4.5). Five of
these children experienced neutropenia and/or thrombocyto-
penia (Table II).
Hepatotoxicity
One child was noted to have a transient rise in alanine
aminotransferase to 60 U 1-', (upper limit = 40) which coin-
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Figure 1 Plasma 6-TG concentrations in children I to 5 over the first 6 h of the study.188 L. LENNARD et al.
600
m
C) 400-
x
z 300-
-200
0.
100
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
Time post-dose (hours)
Figure 2 The accumulation of RBC 6-TGNs in children I to 5 over the first 6 h of the study.
Table I Previous remission 6-MP metabolism. The 6-TG study
Highest 6-TGN
TPMT after 4 weeks 6-TGN after
Number of activities 100% 6-MP 7 days 6-TG
6-TGN (Uml' (pmol8 x 10-8 (pmol8 x J0-8
Subject assays RBCs) RBCs) RBCs)
1 16 20.7 365 1,204
2 38 21.4 317 2,361
3 26 14.9 377 1,114
4 37 22.2 257 1,120
5 23 21 341 1,749
6 16 19.5 228 959
7 30 25.1 257 1,750
Range 16-37 14.9-25.1 257-377 959-2,361
Median 26 20.7 317 1,204*
* = Significantly higher 6-TGN concentrations when compared to those
produced by 6-MP, median difference = 892 pmol, 95% C.I. 743 to 1521,
P = 0.002.
cided with a high 6-TGN concentrations (2,228 pmol 8 x 10-8
RBCs). No other signs of biochemical abnormality were
recorded nor were their any clinical signs of hepatotoxicity.
Discussion
In the patients under study, 6-TGNs accumulated rapidly
within the RBC after oral 6-TG and by 7 days the RBC
6-TGN concentrations were 3.0 to 7.5 times higher than
those produced from long-term 6-MP. Over 3 to 10 months,
of six evaluable children, four experienced cytopenias to a
greater extent than they had previously on 6-MP, so 6-TG
may have a more reliable cytotoxic effect, at least in some
patients. Apart from a single transient elevation of alanine
aminotransferase, no hepatotoxicity was encountered.
There are sparse data on the clinical pharmacology of
6-TG. LePage and Whitecar (1971) reported higher blood
levels of 6-TG after an intravenous (i.v.) compared to an oral
dose in the same patient. The incorporation of 35S 6-TG into
the bone marrow DNA was very small after one dose, but
after five daily doses the guanine of DNA was largely
replaced by 6-TG so they concluded that most cells entered
DNA synthesis in this 5 day period. This, perhaps, forms the
basis of the 5 day dosage schedules subsequently used for
6-TG in many protocols.
A 30-fold range of plasma 6-TG concentrations was
reported in a study of oral 6-TG in acute myeloid leukaemia
(Brox et al., 1981) and the authors suggested that the i.v.
route may be a better way of standardising 6-TG dosage.
Subsequent kinetic studies of 6-TG have used i.v. dosing
schedules on that basis. A study of low dose i.v. 6-TG
(125 mgmr2) demonstrated extensive 6-TG degradation with
75% of the administered dose excreted within 24 h (Lu et al.,
1982). High dose i.v. schedules (700mgm2, every 3 weeks)
have been used in an attempt to saturate the pathways of
6-TG metabolism and elimination and so to allow 6-TG to
persist in the plasma for longer periods of time, (Konits et
al., 1982) and leukopenia was reported in 40% of patients so
treated. Dose limiting myelosuppression was also reported in
a multiple day intermittent schedule of 55 to 65 mg m-2 i.v.
6-TG given daily for 5 days (Kovach et al., 1986).
Interestingly, an often overlooked early study (Leftowitz et
al., 1965) which compared i.v. with oral administration using
35S 6-TG reported higher plasma levels after i.v. dosage but
66 to 85% of the i.v. dose was excreted in 24 h compared to
only 30 to 35% of the p.o. dose. These results are compatible
with our observations on the accumulation of intracellular
6-TGNs after oral 6-TG. A recent report (Liliemark et al.,
1990) of the cellular pharmacokinetics of single dose oral
6-TG in acute myeloid leukaemia describes the continued
accumulation of RBC 6-TGNs throughout the 24 h sampling
period but 6-TGNs were only detected in eight of ten
patients. The accumulation of RBC metabolites was not
mirrored by patients' leukaemic cells, but this could be due
to the short time course of the study coupled with the
difference in the in vivo kinetics of the two cell populations.
Both 6-MP and 6-TG undergo extensive intestinal and6-THIOGUANINE IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA
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Figure 3 The accumulation of RBC 6-TGNs from the start of 6-TG to the first dose adjustment in the seven children studied. For
comparison, the highest 6-TGN concentrations measured after at least 4 weeks 100% 6-MP have been added to the figure
immediately above the '6-MP' label.
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Figure 4 The biphasic loss of RBC 6-TGN after 6-TG withdrawal.
Table H Neutropenia and/or thrombocytopenia during 1st
remission 6-MP and the 6-TG study
1st Remission 6-TG Study
Duration of Cytopenic Duration of Cytopenic
6-MP therapy 6-TG therapy
Subject (weeks) (% time) (weeks) (% time)
1 104 11.5 1 -
2 156 1 22 41
3 104 2 13 23
4 104 7.7 39 7.7
5 104 11.5 13 0
6 43 28 45 33
7 104 11.5 17 64
Cytopenic= Percentage time with a neutrophil count < 1.0 x
I09 1- I and/or a platelet count <100 x I09 1-'.
hepatic 'first-pass' metabolism after oral dosing. The forma-
tion of active nucleotide metabolites catalysed by the enzyme
hypoxanthine phosphoribosyltransferase competes with
TPMT catalysed S-methylation, but 6-TG is a poor substrate
for TPMT when compared to 6-MP. The production of
6-thiouric acid from 6-MP catalysed by xanthine oxidase is a
third competing pathway for 6-MP but for 6-TG to be a
substrate for this enzyme it has to undergo an additional
metabolic step (guanase catalysed 2-deamination) and so the
flux down this path is not as great as for 6-MP. No reduction
in 6-TG dose is required with allopurinol coadministration
(Lu et al., 1982; Zimm et al., 1983).
The goal with any drug therapy is to achieve the desired
biological effects whilst minimising or avoiding undesirable
side effects. In the case of thiopurines for ALL the 'desired
biological effect' is hard to measure, and controlled
myelosuppression is used as a surrogate. The adverse effects
of high dose i.v. 6-TG are nausea and vomiting, leukopenia,
mucositosis, and reversible renal dysfunction (Konits et al.,
1982). Several studies have also reported 6-TG associated
hepatotoxicity (Zimmerman, 1986) but a phase II study of
i.v. 6-TG in refractory multiple myeloma reported that
myelosuppression was the only major toxicity seen (Edelstein
et al., 1990). Myelosuppression was also reported in a Phase
II study of i.v. 6-TG in patients with advanced carcinoma of
the pancreas, and non-haematologic toxicities were mild
(Ajani et al., 1991). Non-cirrhotic portal hypertension was
reported in 18/675 (3%) patients with chronic myeloid
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leukaemia in a randomised trial comparing busulphan with
busulphan and 6-TG, and all the patients who developed
portal hypertension received the 6-TG drug combination
(Shepherd et al., 1991). Busulphan hepatotoxicity with the
subsequent development of portal hypertension has been
previously observed in myeloid leukaemia. (Foadi et al.,
1977) so it is possible that 6-TG may potentiate that side
effect of busulphan.
Fluctuations in metabolite concentrations can, of course,
be due to factors other than vagaries in metabolism. Com-
pliance can be a problem, even with antineoplastic therapy
(Smith et al., 1979), and absorbtion is another major variable
(Riccardi et al., 1986). This is why we chose the highest RBC
6-TGN concentration recorded at presumed steady-state for
6-MP to be reflective of the true capacity for 6-TGN forma-
tion when making our comparisons with metabolite produc-
tion from 6-TG.
In this study we have demonstrated the formation of high
concentrations of intracellular 6-TGNs in children who failed
to achieve anything like the same concentrations while taking
conventional doses of 6-MP in their previous remission. Most
of them developed more cytopenias. Other than myelosup-
pression and a single transient elevation of alanine amino-
transferase (cause unclear) in one patient no toxic effects of
therapy were observed.
Relapse in ALL reduces the chances of long-term disease
free survival to 10-20% (Butturini et al., 1987), and in some
children is undoubtedly the result of failure of continuing or
'maintenance' therapy. Where such failure is due to 6-MP
'resistance' - constitutionally high TPMT activity - it might
be prevented by the use of 6-TG instead of 6-MP in initial
therapy. Indeed, it would be interesting to study the straight
substitution of 6-TG for 6-MP in all patients in the context
of a prospective randomised controlled clinical trial.
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